# MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

> **NCT07391839** · PHASE1 · RECRUITING · sponsor: **Suzhou Mednovo Yi Medical Technology Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Hepatoma
- Unresectable Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** MDN-001 Injection(Yttrium-90 Microsphere Injection)

## Key facts

- **NCT ID:** NCT07391839
- **Lead sponsor:** Suzhou Mednovo Yi Medical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391839, "MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT07391839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*